Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 819-825

  Parry, Christopher M ^a,d,e   Ho, Vo Anh ^c   Phuong, Le Thi ^c   Van Be Bay, Phan ^c   Lanh, Mai Ngoc ^c   Tung, Le Thanh ^c   Tham, Nguyen Thi Hong ^c   Wain, John ^a,d,f   Hien, Tran Tinh ^b   Farrar, Jeremy J ^a,d  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c Dong Thap Provincial Hospital   (Viet Nam)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CHLORAMPHENICOL; COTRIMOXAZOLE; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG SENSITIVITY; DRUG TOLERANCE; FECES CULTURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PARAMETER; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA ENTERICA; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SCHOOL CHILD; SEROTYPE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TYPHOID FEVER; VIET NAM;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; OFLOXACIN; SALMONELLA ENTERICA; TREATMENT OUTCOME; TYPHOID FEVER;

EID: 33847648022     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00447-06     Document Type: Article

References (37)

1. Aarestrup, F. M., C. Wiuff, K. Mølbak, and E. J. Threlfall. 2003. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob. Agents Chemother. 47:827-829.
2. Ackers, M.-L., N. D. Fuhr, R. V. Tauxe, and E. D. Mintz. 2000. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States. JAMA 283:2668-2673.
3. Bethell, D. B., N. P. J. Day, M. D. Nguyen, C. McMullin, T. L. Ha, T. H. T. Dong, T. N. M. Le, T. M. L. Nguyen, Q. D. Nguyen, V. Ha, A. P. MacGowan, L. O. White, and N. J. White. 1996. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob. Agents Chemother. 40:2167-2172.
4. Bethell, D. B., T. T. Hien, L. T. Phi, N. P. Day, H. Vinh, N. M. Duong, N. V. Len, L. V. Chuong, and N. J. White. 1996. Effects on growth of single short courses of fluoroquinolones. Arch. Dis. Child. 74:44-46.
5. Bhutta, Z. A., I. A. Khan, and M. Shadmani. 2000. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled field trial in Pakistan. Antimicrob. Agents Chemother. 44:450-452.
6. Booker, B. M., P. F. Smith, A. Forrest, J. Bullock, P. Kelchlin, S. M. Bhavnani, R. N. Jones, and P. G. Ambrose. 2005. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob. Agents Chemother. 49:1775-1781.
7. Butler, T., R. W. Frenck, R. B. Johnson, and R. Khakhria. 2001. In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. J. Antimicrob. Chemother. 47:455-458.
8. Butler, T., C. Sridhar, M. Daga, K. Pathak, R. B. Pandit, R. Khakhria, C. N. Potkar, M. T. Zelasky, and R. B. Johnson. 1999. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J. Antimicrob. Chemother. 44:243-250.
9. Cao, X. T. P., R. Kneen, N. T. Ann, T. D. Luat, N. J. White, and C. M. Parry. 1999. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatr. Infect. Dis. J. 18:245-248.
10. Chinh, N. T., C. M. Parry, N. T. Ly, H. D. Ha, M. X. Thong, T. S. Diep, J. Wain, N. J. White, and J. J. Farrar. 2000. A randomised controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob. Agents Chemother. 44:1855-1859.
11. Cooke, F. J., J. Wain, and E. J. Threlfall. 2006. Fluoroquinolone resistance in Salmonella typhi. Br. Med. J. 333:353-354.
12. Crump, J. A., T. J. Barrett, J. T. Nelson, and F. J. Angulo. 2003. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin. Infect. Dis. 37:75-81.
13. Crump, J. A., S. P. Luby, and E. D. Mintz. 2004. The global burden of typhoid fever. Bull. W. H. O. 82:346-353.
14. Doherty, C. P., S. K. Saha, and W. M. Cutting. 2000. Typhoid fever, ciprofloxacin and growth in young children. Ann. Trop. Paediatr. 20:297-303.
15. Dutta, P., U. Mitra, S. Dutta, A. De, M. K. Chatterjee, and S. K. Bhattacharya. 2001. Ceftriaxone therapy in ciprofloxacin treatment failure in children. Indian J. Med. Res. 113:210-213.
16. Forrest, A. D., E. D. Nix, C. H Hallow, T. F Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents. Chemother. 37:1073-1081.
17. Foulds, G., R. M. Shepard, and R. B. Johnson. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A):73-82.
18. Frenck, R. W., Jr., A. Mansour, I. Nakhla, I. Y. Sultan, S. Putnam, T. Wierzba, M. Morsy, and C. Knirsch. 2004. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin. Infect. Dis. 38:951-957.
19. Frenck, R. W., Jr., I. Nakhla, Y. Sultan, S. B. Bassily, Y. F. Girgis, J. David, T. C. Butler, N. I. Girgis, and M. Morsy. 2000. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin. Infect. Dis. 31:1134-1138.
20. Gasem, M. H., M. Keyter, W. M. V. Dolmans, J. V. van der Ven-Jongekrijg, R. Djokomoeljanto, and J. W. M. van der Meer. 2003. Persistence of salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. Antimicrob. Agents Chemother. 47:1727-1731.
21. Girgis, N. I., T. Butler, R. W. Frenck, Y. Sultan, F. M. Brown, D. Tribble, and R. Khakhria. 1999. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob. Agents Chemother. 43:1441-1444.
22. Hasan, R., F. J. Cooke, S. Nair, B. N. Harish, and J. Wain. 2005. Typhoid and paratyphoid fever. Lancet 366:1603-1604.
23. Mehta, G., V. S. Randhawa, and N. P. Mohapatra. 2001. Intermediate susceptibility to ciprofloxacin in Salmonella typhi strains in India. Eur. J. Clin. Microbiol. Infect. Dis. 20:760-761.
24. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial sensitivity testing; disc diffusion. Supplemental tables. M100-S13 (M2). NCCLS, Wayne, PA.
25. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-sixth edition. Approved standard. NCCLS document M7-A6. NCCLS, Wayne, PA.
26. Panteix, G., B. Guillaumond, R. Harf, A. Desbos, V. Sapin, M. Leclercq, and M. Perrin-Fayolle. 1993. In-vitro concentration of azithromycin in human phagocytic cells. J. Antimicrob. Chemother. 31(Suppl. E):1-4.
27. Parry, C. M. 2004. The treatment of multidrug resistant and nalidixic acid resistant typhoid fever in Vietnam. Trans. R. Soc. Trop. Med. Hyg. 98:413-422.
28. Parry, C. M., T. T. Hien, G. Dougan, N. J. White, and J. J. Farrar. 2002. Typhoid fever. N. Engl. J. Med. 347:1770-1782.
29. Rakita, R. M., K. Jaques-Palaz, and B. E. Murray. 1994. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob. Agents Chemother. 38:1915-1921.
30. Rodrigues, C., S. Shenai, and A. Mehta. 2003. Enteric fever in Mumbai, India: the good news and the bad news. Clin. Infect. Dis. 36:535.
31. Rupali, P., O. C. Abraham, M. V. Jesudason, T. J. John, A. Zachariah, S. Sivaram, and D. Mathai. 2004. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype typhi. Diagn. Microbiol. Infect. Dis. 49:1-3.
32. Saha, S. K., S. Y. Talukder, M. Islam, and S. Saha. 1999. A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. Pediatr. Infect. Dis. J. 18:387.
33. Smith, M. D., N. M. Duong, N. T. T. Hoa, J. Wain, H. D. Ha, T. S. Diep, N. P. J. Day, T. T Hien, and N. J. White. 1994. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 38:1716-1720.
34. Wain, J., T. S. Diep, V. A. Ho, A. M. Walsh, N. T. T. Hoa, C. M. Parry, and N. J. White. 1998. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J. Clin. Microbiol. 36:1683-1687.
35. Wain, J., N. T. T. Hoa, N. T. Chinh, H. Vinh, M. J. Everett, T. S. Diep, N. P. Day, T. Solomon, N. J. White, L. J. Piddock, and C. M. Parry. 1997. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25:1404-1410.
36. Wallace, M. R., A. A. Yousif, G. A. Mahroos, T. Mapes, E. J. Threlfall, B. Rowe, and K. C. Hyamms. 1993. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur. J. Clin. Microbiol. Infect. Dis. 12:907-910.
37. Yee, C. L., C. Dulfy, P. G. Gerbino, S. Stryker, and G. J. Noel. 2002. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr. Infect. Dis. J. 21:525-529.